Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Hematology

Why Is an Excisional Biopsy Often Needed to Diagnose DLBCL?

At a Glance

An excisional biopsy is often preferred for suspected DLBCL because examining an intact lymph node preserves its architecture and provides enough tissue for flow cytometry, immunohistochemistry, and genetic testing. A core biopsy may be used when surgery is unsafe.

If your doctor suspects you have Diffuse Large B-Cell Lymphoma (DLBCL), they will likely recommend an excisional biopsy—a surgical procedure to remove an entire enlarged lymph node. It is natural to wonder why a surgeon needs to remove a whole lymph node when simple needle biopsies are commonly used to diagnose other cancers. The short answer is that diagnosing DLBCL often requires a pathologist to examine the intact “architecture” of the lymph node, which a needle biopsy usually cannot provide [1].

However, an excisional biopsy is not universally required for every patient. It is considered the ideal standard when it can be performed safely, but if the lymph node is deep or surgery carries too much risk, your care team may rely on other sampling methods [2].

The Limits of Needle Biopsies

A Fine-Needle Aspiration (FNA) uses a thin needle to pull a small sample of fluid and cells from a tumor. While this is less invasive, it only captures a limited scattering of cells and does not preserve the tissue’s natural structure [3]. Imagine trying to understand the plot of a movie by looking at three random screenshots; you might see the characters, but you will not know the context of what is happening.

Additionally, if a lymph node contains areas of dead tissue (necrosis), a needle biopsy might accidentally draw from these dead zones [4][5]. This can result in a sample that cannot be tested properly. FNA can sometimes help with preliminary screening or a test called flow cytometry (which looks at cells suspended in fluid), but it often cannot establish the full lymphoma classification by itself [6].

A Core Needle Biopsy (CNB) uses a slightly larger needle to remove a small cylinder of tissue. A CNB provides more information than an FNA and is commonly used if an excisional surgery is unsafe or the lymph node is difficult to reach [2][7]. If a core biopsy does not provide a definitive diagnosis, your doctor may then recommend a repeat biopsy or an excision [1].

The Importance of Lymph Node Architecture

To definitively diagnose DLBCL, a pathologist must look at the lymph node’s architecture—the physical arrangement and growth pattern of the cells within the node [1].

Many types of large B-cell lymphomas share overlapping features, making them very difficult to tell apart by just looking at individual cells [8]. For example, DLBCL must be carefully distinguished from conditions like marginal-zone lymphoma or a fast-growing version of mantle-cell lymphoma [9]. Some lymphomas also start as slow-growing diseases and later transform into DLBCL. By examining the whole lymph node, the pathologist can see the physical boundaries of the cells and how they interact with their environment. This big-picture view is essential for an accurate diagnosis [10][11].

Getting Enough Tissue for Specialized Tests

Modern medicine relies on advanced molecular and genetic tests to understand exactly how the cancer behaves. While an excisional biopsy does not guarantee a perfect sample, it provides the best chance of gathering enough high-quality tissue for a complete diagnostic workup [1][10]:

  • Immunohistochemistry (IHC): This test uses special dyes to detect specific proteins in or on the lymphoma cells. IHC helps determine your “cell-of-origin” subtype of DLBCL, such as Germinal-Center B-cell-like (GCB) or Activated B-cell-like (ABC) [12][13].
  • FISH Testing: Fluorescence In Situ Hybridization (FISH) is a genetic test that looks for specific gene rearrangements in the MYC, BCL2, and BCL6 genes [14]. Identifying these rearrangements is critical for identifying specific high-grade lymphomas (sometimes referred to as “double-hit” lymphomas), which can directly influence your classification and treatment decisions [15][16].

While it is technically possible to perform FISH testing on a core needle biopsy, having a full lymph node gives the laboratory more tissue to allocate across morphology, flow cytometry, IHC, and genetic testing [4][17]. Note that the results for these different tests often arrive in stages over several days to weeks, rather than all at once.

Surgical Risks and Recovery

While an excisional biopsy for a superficial node (like in the neck or armpit) might be done as an outpatient procedure under local anesthesia, nodes located deep in the chest or abdomen require more involved surgery and general anesthesia. The risks—which can include bleeding, infection, pain, scarring, or nerve damage—depend entirely on the lymph node’s location. Your surgeon should explain the specific risks, the type of anesthesia required, and the expected recovery time before you decide on the procedure.

Common questions in this guide

Why is an excisional biopsy often preferred when DLBCL is suspected?
An excisional biopsy removes the entire lymph node, allowing a pathologist to assess its architecture—the pattern and relationships of the cells—not just a small collection. This broader view can help distinguish DLBCL from other lymphomas and identify whether a slower-growing lymphoma has transformed.
Can a core needle biopsy be used instead of an excisional biopsy for DLBCL?
Yes. A core biopsy may be chosen when a lymph node is deep, difficult to reach, or surgery would pose too much risk, and it provides more tissue than fine-needle aspiration. If the sample does not support a definitive diagnosis, a repeat biopsy or excision may be needed.
Why may fine-needle aspiration be insufficient to diagnose DLBCL?
Fine-needle aspiration collects scattered cells but usually does not preserve the lymph node’s structure. It can help with an initial assessment or flow cytometry, but it may not provide enough context to classify the lymphoma fully, especially if the needle samples dead tissue.
What tests may be performed on tissue from a DLBCL biopsy?
A pathology workup may include immunohistochemistry to identify proteins, flow cytometry to analyze cell markers, and fluorescence in situ hybridization, or FISH, to look for rearrangements in the MYC, BCL2, and BCL6 genes. These results help classify the lymphoma and inform treatment planning, and they may be reported at different times.
How long do DLBCL biopsy results take?
Results often arrive in stages over several days to weeks. The initial tissue examination may be available before flow cytometry, immunohistochemistry, or genetic testing is complete. Ask your care team which results are ready and when the full report is expected.
What risks come with an excisional lymph node biopsy?
Risks depend on the lymph node’s location and the anesthesia and surgery required. They may include bleeding, infection, pain, scarring, or nerve damage, while biopsies of deep nodes in the chest or abdomen can require more involved surgery. Your surgeon should explain your individual risks and expected recovery.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given the location of my enlarged lymph node, what are the specific surgical risks of an excisional biopsy versus a core needle biopsy?
  2. 2.If a core needle biopsy is planned, how will the pathology team ensure they gather enough tissue for flow cytometry, IHC, and FISH testing?
  3. 3.Will my biopsy sample be sent to a hematopathologist (a pathologist who specializes in blood cancers) for review?
  4. 4.What is the expected timeline for getting the complete results back, and do they arrive in stages?
  5. 5.If a core biopsy is non-diagnostic, what will our next step be?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment.

    Liu Y, Barta SK

    American journal of hematology 2019; (94(5)):604-616 doi:10.1002/ajh.25460.

    PMID: 30859597
  2. 2

    Role of core needle biopsy in primary breast lymphoma.

    Bicchierai G, Rigacci L, Miele V, et al.

    La Radiologia medica 2017; (122(9)):651-655 doi:10.1007/s11547-017-0773-3.

    PMID: 28510806
  3. 3

    Lymph node cytopathology: Essential ancillary studies as applied to lymphoproliferative neoplasms.

    Jin M, Wakely PE

    Cancer cytopathology 2018; (126 Suppl 8()):615-626 doi:10.1002/cncy.22013.

    PMID: 30156771
  4. 4

    Performance of MYC, BCL2, and BCL6 break-apart FISH in small biopsies with large B-cell lymphoma: a retrospective Cytopathology Hematopathology Interinstitutional Consortium study.

    Menke JR, Aypar U, Bangs CD, et al.

    Frontiers in oncology 2024; (14()):1408238 doi:10.3389/fonc.2024.1408238.

    PMID: 38903717
  5. 5

    Primary Diffuse Large B-Cell Lymphoma Mimicking a Dental Abscess: A Case Report.

    Aghdam HN, Paya L, Zohrabi M

    Clinical case reports 2026; (14(3)):e72139 doi:10.1002/ccr3.72139.

    PMID: 41767087
  6. 6

    CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples.

    Cozzolino I, Varone V, Picardi M, et al.

    Cancer cytopathology 2016; (124(2)):135-43 doi:10.1002/cncy.21626.

    PMID: 26414904
  7. 7

    Limited Tissue Biopsies and Hematolymphoid Neoplasms.

    Ingersoll KF, Zhao Y, Harrison GP, et al.

    American journal of clinical pathology 2019; (152(6)):782-798 doi:10.1093/ajcp/aqz107.

    PMID: 31365922
  8. 8

    A Practical Approach to Diagnosis of B-Cell Lymphomas With Diffuse Large Cell Morphology.

    King JF, Lam JT

    Archives of pathology & laboratory medicine 2020; (144(2)):160-167 doi:10.5858/arpa.2019-0182-RA.

    PMID: 31990228
  9. 9

    Complexities in the diagnosis of large B-cell lymphomas, classic Hodgkin lymphomas and overlapping peripheral T-cell lymphomas simplified: An evidence-based guide.

    Wen KW, Fakhri B, Menke J, et al.

    Annals of diagnostic pathology 2020; (46()):151534 doi:10.1016/j.anndiagpath.2020.151534.

    PMID: 32473554
  10. 10

    From Biopsy to Diagnosis: Navigating Aggressive B-Cell Lymphomas in Practice.

    Halcu G, Evsei-Seceleanu A, Cerbu M, et al.

    Medicina (Kaunas, Lithuania) 2025; (61(5)) doi:10.3390/medicina61050842.

    PMID: 40428800
  11. 11

    Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues.

    Grimm KE, O'Malley DP

    Annals of diagnostic pathology 2019; (38()):6-10 doi:10.1016/j.anndiagpath.2018.09.014.

    PMID: 30380402
  12. 12

    Molecular Diagnostic Review of Diffuse Large B-Cell Lymphoma and Its Tumor Microenvironment.

    Ta R, Yang D, Hirt C, et al.

    Diagnostics (Basel, Switzerland) 2022; (12(5)) doi:10.3390/diagnostics12051087.

    PMID: 35626243
  13. 13

    [Diffuse Large B cell Lymphoma -  Modern Dia-gnostics and Molecularly Targeted Treatment].

    Pytlík R, Trněný M

    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 2015; (28 Suppl 3()):3S64-72.

    PMID: 26489504
  14. 14

    The predictive value of immunohistochemistry for MYC, BCL2, and BCL6 in fluorescence in situ hybridization in aggressive mature B-cell lymphomas and re-evaluation according to the 5 th edition of the World Health Organization classification: A single-center 9-year experience.

    Bassullu N, Tokat F, Guvendir I, et al.

    Indian journal of pathology & microbiology 2026; (69(1)):29-39 doi:10.4103/ijpm.ijpm_60_25.

    PMID: 41717964
  15. 15

    [The incidence of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in diffuse large B-cell lymphoma].

    Li M, Zhang QL, Zhao W, et al.

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2021; (42(2)):124-128 doi:10.3760/cma.j.issn.0253-2727.2021.02.006.

    PMID: 33858042
  16. 16

    Clinical Significance of BCL2, C-MYC, and BCL6 Genetic Abnormalities, Epstein-Barr Virus Infection, CD5 Protein Expression, Germinal Center B Cell/Non-Germinal Center B-Cell Subtypes, Co-expression of MYC/BCL2 Proteins and Co-expression of MYC/BCL2/BCL6 Proteins in Diffuse Large B-Cell Lymphoma: A Clinical and Pathological Correlation Study of 120 Patients.

    Ting CY, Chang KM, Kuan JW, et al.

    International journal of medical sciences 2019; (16(4)):556-566 doi:10.7150/ijms.27610.

    PMID: 31171907
  17. 17

    High performance of multiplex fluorescence in situ hybridization to simultaneous detection of BCL2 and BCL6 rearrangements: useful application in the characterization of DLBCLs.

    Marino FZ, Aquino G, Brunelli M, et al.

    Virchows Archiv : an international journal of pathology 2021; (479(3)):565-573 doi:10.1007/s00428-021-03084-8.

    PMID: 33768318

This page explains why doctors may recommend an excisional biopsy for suspected DLBCL for informational purposes only and does not constitute medical advice. Discuss the safest biopsy approach and your results with your hematologist, oncologist, surgeon, or pathologist.

Get notified when new evidence is published on Diffuse large B-cell lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.